Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;11(11):3280-3288.
doi: 10.1111/1759-7714.13669. Epub 2020 Sep 22.

Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure

Dai Sonoda  1   2 , Yosuke Matsuura  1 , Yasuto Kondo  1   2 , Junji Ichinose  1 , Masayuki Nakao  1 , Hironori Ninomiya  3 , Yuichi Ishikawa  3 , Makoto Nishio  4 , Sakae Okumura  1 , Yukitoshi Satoh  2 , Mingyon Mun  1
Affiliations

Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure

Dai Sonoda et al. Thorac Cancer. 2020 Nov.

Abstract

Background: The prognosis of postoperative recurrence in patients with non-small cell lung cancer (NSCLC) is poor. However, depending on the recurrence patterns and treatment options, some patients can achieve long-term survival following recurrence. In this study, we investigated the clinicopathological characteristics of NSCLC patients with curable disease who developed postoperative recurrence.

Methods: This retrospective study enrolled 535 patients who had developed recurrence from among 1760 consecutive patients with NSCLC who underwent curative resection from 1990 to 2008. Post-recurrence cure was defined as being cancer-free for at least five years after treatment for recurrence in patients who had undergone radical local treatment or chemotherapy. The clinicopathological characteristics associated with post-recurrence cure were analyzed.

Results: Among 535 patients who developed recurrence, 24 (4.5%) achieved post-recurrence cure. The median post-recurrence follow-up duration was 151 (85-275) months for those who achieved post-recurrence cure. The solitary recurrent lesions and local treatment for the initial recurrence site were significantly more for patients who could be cured after they developed recurrence. All patients with post-recurrence cure received only radical local treatment for the recurrent lesions.

Conclusions: Some patients with solitary recurrent NSCLC lesions can be cured with only radical local treatment.

Key points: Significant findings of the study The post-recurrence cure patients maintained a cancer-free status for five years after treatment for recurrence without a second recurrence. All patients with post-recurrence cure received only radical local treatment for recurrence and had significantly higher number of solitary recurrent lesions. What this study adds Some patients with solitary recurrent NSCLC lesions after resection can be cured with only radical local treatment.

Keywords: Lung; radiotherapy; recurrence; thoracic surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The schematic diagram of the study.
Figure 2
Figure 2
Kaplan–Meier curves for post‐recurrence survival (PRS) in 535 patients with recurrence. The five‐year PRS rate was 18.8%.
Figure 3
Figure 3
Kaplan–Meier curves for post‐recurrence survival (PRS) in patients with and without post‐recurrence cure who achieved five‐year survival after recurrence. The 10‐year PRS rate in patients with post‐recurrence cure was 90.9%. The 10‐year PRS rate was 26.7% in patients who failed to achieve post‐recurrence cure. formula imagepost‐recurrence cure and formula imagenon‐post‐recurrence cure.
See this image and copyright information in PMC

References

    1. Martin J, Ginsberg RJ, Venkatraman ES et al Long term results of combined‐modality therapy in resectable non‐small‐cell lung cancer. J Clin Oncol 2002; 20: 1989–95. - PubMed
    1. Taylor MD, Nagji AS, Bhamidipati CM et al Tumor recurrence after complete resection for non‐small cell lung cancer. Ann Thorac Surg 2012; 93: 1813–20. - PubMed
    1. Gourcerol D, Scherpereel A, Debeugny S, Porte H, Cortot AB, Lafitte JJ. Relevance of an extensive follow‐up after surgery for nonsmall cell lung cancer. Eur Respir J 2013; 42: 1357–64. - PubMed
    1. Endo C, Sakurada A, Notsuda H et al Results of long term follow‐up of patients with completely resected non‐small cell lung cancer. Ann Thorac Surg 2012; 93: 1061–8. - PubMed
    1. Ohe Y, Ohashi Y, Kubota K et al Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non‐small‐cell lung cancer: Four‐Arm Cooperative Study in Japan. Ann Oncol 2007; 18: 317–23. - PubMed